A committee with the U.S. Centers for Disease Control and Prevention on Friday recommended resuming the use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots.

Out of nearly 8 million people vaccinated before the U.S. suspended J&J’s shot, health officials uncovered 15 cases of a highly unusual kind of blood clot, three of them fatal. All were women, and most younger than 50.

Use of Johnson & Johnson’s Covid-19 vaccine should be summarized in the US, as specified under its emergency use authorization by the US Food and Drug Administration, advisers to the US Centers for Disease Control and Prevention recommended.

Regulators paused its use last week to review reports of rare but serious blood clots associated with low blood platelets, Reuters reports.

“The benefits do clearly outweigh the risk from a population and individual perspective,” said Dr Beth Bell, a member of the advisory panel and a clinical professor in the department of global health at the University of Washington.

“It’s a new risk. It’s admittedly an extremely small risk and smaller than many other risks that we choose to take every day, ”she added.

Advisers to the CDC voted 10-4 to resume the shot’s emergency use authorization in the U.S. for everyone 18 and older. The panel said Friday that the vaccine’s benefits outweigh that serious but small risk — especially against a virus that’s still infecting tens of thousands of Americans every day.

The U.S. government will rapidly weigh that recommendation in deciding the next steps. The CDC generally follows its advisers’ recommendations, and J&J vaccinations could resume quickly.